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MDCK, LLC-PK1 and RK 13 renal cells were exposed to different OTA concentrations (2.5 to
25 g OTA/mL of medium) for 24 hours. 2.5 g OTA/mL significantly reduced the number of
living RK 13 cells to 69.4 %, LLC-PK1 cells to 34.5 % and MDCK cells to 27.5 %, as com-
pared to untreated control cells. Effects of OTA on cell morphology were examined by haema-
toxylin/eosin or phalloidin-FITC/propidium iodide staining. 12 %, 11 % and 8.2 % apoptotic
cells were observed in MDCK, LLC-PK1 and RK 13 cells treated with 2.5 g OTA/mL, re-
spectively. The structure of actin cytoskeleton showed significant changes in OTA-treated cells.
Release of LDH into the culture medium was more abundant in MDCK and LLC-PK1 cells.
OTA induced apoptotic and/or necrotic cell death in a cell type- and concentration-dependent
manner. The results suggest that MDCK and LLC-PK1 cells are more sensitive to OTA than
RK 13 cells.
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INTRODUCTION
Ochratoxin A (OTA) is a widespread mycotoxin produced
by several Aspergillus and Penicillium species.1–3 Inges-
tion of OTA-contaminated feed or food has been associat-
ed with nephrotoxic,4 genotoxic5,6 and carcinogenic7–10
effects, perturbation of normal blood coagulation11 and
immune response.12 OTA is considered as one of the
etiologic agents involved in the development of endemic
nephropathy10,13,14 in humans as well as in tubular-inter-
stitial nephropathy in humans and animals. The toxin af-
fects different nephron functions, including renal blood
flow, glomerular and tubular function.4,15–18 The main
targets of OTA are epithelial cells of proximal and distal
tubules and interstitial cells. OTA induces defects of the
organic anion transport mechanism located on the brush
border membranes of the proximal convoluted tubule
cells and basolateral membrane.19 It has been found that
the middle (S2) and the terminal (S3) segments of the
proximal tubule are the most sensitive to the toxic ef-
fects of OTA. These effects are observed through a sig-
nificant decrease in mitochondrial and cellular ATP con-
tents after treatment with 0.05 mmol/L OTA.20
Long-term effects of OTA on kidneys are usually
primarily related to lesions of proximal tubules, follow-
ed by spontaneous damage of the glomeruli and involu-
tion of the interstitia.4 On the other hand, it was shown
that acute OTA intoxication resulted in massive acido-
philic degeneration with necrosis and desquamation of
epithelium in proximal tubules.21
The mechanism of OTA cytotoxicity mainly de-
pends on the toxin concentration and on the period of or-
ganism/cell exposure to OTA. Lower toxin concentra-
tions affect a cell in a specific way through interactions
with secondary messengers and other cell targets, which
subsequently activate mitogen-activated protein kinases
(MAPKs)22 or inhibit certain carriers and disturb normal
cell homeostasis.17 At relatively high concentrations se-
vere disturbances in the cell metabolism are observed,
such as inhibition of the synthesis of macromolecules,23
stimulation of lipid peroxidation24,25 or disintegration of
mitochondria26 and necrosis of epithelial tubule cells.21
In addition, previous studies implicate stimulation of oxi-
dative stress in OTA-induced cytotoxicity.25,27–31
OTA-dependent induction of cell death has been re-
ported both in vivo and in vitro: in rat kidney,29,32 in mice
liver,28 in human lymphocytes,33 in MDCK and HeLa
cells,34–36 in LLC-PK1 cells,30 in V79 and CV-1 cells,
respectively.31
Cell death can generally proceed via necrosis or
apoptosis. Necrosis is a deregulated form of cell death
induced by strong pathological stimuli. On the other
hand, apoptosis is an organized, highly regulated physio-
logical and pathological form of cell death. In contrast to
the swelling and membrane rupture being typical of ne-
crosis, a cell undergoing apoptosis rapidly condenses
into small enclosed apoptotic bodies, which can be con-
sequently removed by phagocytosis. Apoptosis can be
induced by multiple stimuli, including radiation, heat,
cytokines, free radicals and/or toxins.37–39 Apoptosis is
an active mode of cell death that promotes cell loss dur-
ing both acute and chronic renal damage. Numerous re-
ports have indicated that alterations in the regulation of
cell death/survival contribute to the pathogenesis of
many human diseases.40,41 Mechanisms of cell death in-
duced by OTA have not been fully characterized.
The aim of the present study was to examine the
toxicity of relatively high OTA concentrations on renal
cells, as well as to establish the mode and the extent of
cell death provoked by OTA. We performed our research
on three different cell lines: LLC-PK1 (pig kidney cell
line, corresponding to the proximal tubule epithelial
cells), MDCK (Madin-Darby canine kidney cell line,
corresponding to the distal tubule epithelial cells) and
RK 13 (rabbit kidney cell line).
EXPERIMENTAL
Cell Culture
Kidney cell lines were maintained in Eagle´s MEM culture
medium supplemented with 10 % foetal bovine serum (FBS),
100 IU/mL ( 60 g/mL) penicillin, 100 g/mL streptomy-
cin and 2.5 g/mL amphotericin B in a humidified atmo-
sphere containing 5 % CO2 at 37 oC. MDCK (Madin-Darby
canine kidney cell line), LLC-PK1 (pig kidney cell line) and
RK 13 (rabbit kidney cell line) cells were plated in 6 or 12
well-plates at a plating density of 105–106 cells/mL.
Treatment
MDCK, LLC-PK1 and RK13 cell lines were treated with
2.5, 5, 15 and 25 g OTA/mL for 24 hours. Stock solution
(10 mg/mL) was prepared by dissolving OTA in ethanol and
was protected from light. The final OTA concentration was
obtained by appropriate dilution of the stock solution in the
respective culture medium. The final ethanol concentration
in the medium of treated or control cells was 0.25 % for
each sample.
Morphological Characterization
Approximately 5104/mLMDCK, LLC-PK1 and RK 13 cells
were seeded onto rounded glass coverslips placed in 6 or 12
well-plates. 80–90 % confluence was reached after 24–48
hours of incubation. The cells were then exposed to differ-
ent OTA concentrations. The cells were washed with phos-
phate-buffered saline (PBS, 20 mmol dm–3 phosphate buf-
fer, 150 mmol dm–3 NaCl, pH = 7.2) and the adherent cells
were fixed and stained with haematoxylin and eosin (H + E)
using the Kiernan method.42 The effects of OTA in MDCK,
LLC-PK1 and RK 13 cells, including apoptotic and mitotic
changes, were quantified after 24 h treatment.
TUNEL Assay
TUNEL was carried out using dUTP–fluorescein isothio-
cyanate (dUTP–FITC), according to the instructions of the
manufacturer (In Situ Cell Death Detection Kit, Boehringer
Mannheim, Germany). Adherent cells were fixed onto glass
slides with 4 % paraformaldehyde in PBS, and the frag-
mented DNA of apoptotic cells was measured by catalytic
incorporation of FITC-labelled dUTP at 3'-OH ends using
the terminal deoxynucleotidyl transferase. The dUTP-FITC
labelled DNA was visualized using fluorescence micro-
scopy (Olympus BX50).
Actin Cytoskeleton Stained with Phalloidin-FITC
Adhered cells were fixed onto coverslips with 3.5 % para-
formaldehyde, washed in PBS, permeabilized with 0.1 %
Triton X-100 for 15 min and washed again in PBS. The
cytoskeleton structure was studied by staining actin filaments
with 50 L of phalloidin-FITC solution (Sigma) for 15 min
(24 L of 0.05 mg/mL phalloidin-FITC in ethanol dissolved
in 1.2 mL PBS). Cell nuclei were simultaneously labelled
with 50 L of propidium iodide solution for 5 min (20 g
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propidium iodide in 1 mL PBS). The phalloidin-FITC and
propidium iodide stained cells were visualized using fluo-
rescence microscopy (Olympus BX50).
Lactate Dehydrogenase (LDH) Assay
Catalytic activity of LDH was determined by the kinetic
UV test using 50 L of culture supernatant, 2 mL of work-
ing reagent (61.43 mmol dm–3 Tris buffer, 0.20 mmol dm–3
NADH, pH = 7.4) and 10 L of substrate (21.5 mmol dm–3
pyruvate). Absorbances were measured at 339 nm every 30 s
during a 5-min time period with a Pye-Unicam SP8-100
UV/Vis spectrophotometer.
Statistical Analysis
Obtained data were analyzed by the one-way analysis of
variance (ANOVA) followed by a multiple comparison
method (Dunnett’s test). The level of P<0.05 was consid-
ered statistically significant for all the tests performed.
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Figure 1. Effects of OTA on cell viability. MDCK, LLC-PK1 and RK
13 cells were treated with 2.5, 5, 15 and 25 g OTA/mL for
24 hours. Cell viability was examined by haematoxylin and eosin
staining (a, b) and by the LDH release assay (c). Values for un-
treated control cells were taken as 100 % (a, c) or represent the
number of apoptotic cells in the total number of cells counted (b).
Data represent mean  SD of six replicates for each experimental
condition. Significantly different from control values, *P<0.05.
TABLE I. The number of total adherent, apoptotic and mitotic cells in untreated and treated MDCK, LLC-PK1 and RK 13 stained with
haematoxylin and eosin(a)
Cell lines Total cell number Apoptotic cells Mitotic cells Mitosis/1000 stained cells
MDCK
Control 385  19 0.6  0.1 7.0  1.1 18  2.9
2.5 g OTA/mL 106  16 12.7  2.3 0,3  0.1 3  0.9
5 g OTA/mL 17  3.1 4.8  0.7 0 0
15 g OTA/mL 1  0.2 0 0 0
25 g OTA/mL 0 0 0 0
LLC-PK1
Control 336  21 0,7  0.1 6,3  0.9 19  2.7
2.5 g OTA/mL 116  18 13,1  1.3 0.2  0.1 1.7  0.9
5 g OTA/mL 26  3 5,3  0.3 0 0
15 g OTA/mL 2  0.1 2  0.1 0 0
25 g OTA/mL 1  0.1 1  0.1 0 0
RK 13
Control 385  24 5,7  1.1 0,7  0.1 1.8  0.3
2.5 g OTA/mL 267  19 21.9  3.9 0 0
5 g OTA/mL 190  12 25,2  2.6 0 0
15 g OTA/mL 153  13 66,2  5.1 0 0
25 g OTA/mL 119  8 9,4  1.3 0 0
(a)Values represent the means  SD of total, apoptotic and mitotic cells calculated in 15 optical fields (magnification 200)
RESULTS AND DISCUSSION
We have examined the effects of different OTA concen-
trations (2.5, 5, 15 and 25 g OTA/mL) on the viability
of MDCK, LLC-PK1 and RK 13 cells after 24 hours of
treatment. The impairments of the renal cell function ob-
served after exposure to OTA depended significantly on the
toxin concentration, as described in many studies. Con-
centrations of OTA below 10–6 mol dm–3 (<0.403 g/mL)
are considered as low, and those above 10–6 mol dm–3
are considered as high OTA concentrations for the ma-
jority of cell lines.15
We found that the number of living cells significant-
ly decreased with increasing the concentration of OTA.
2.5 g OTA/mL reduced the number of living RK 13
cells to 69.4 %, LLC-PK1 cells to 34.5 % and MDCK
cells to 27.5 %, as compared to untreated control cells
(Table I, Figure 1a). This means that the 2.5 g OTA/mL
concentration reduced the number of living MDCK and
LLC-PK1 cells to less than 50 % of the control samples.
Kitabatake and co-workers found that the LD50 value for
OTA was 2 ppm (2 g/mL) in MDCK cells exposed to
OTA for 72 hours.34 On the other hand, the percentage
of living RK 13 cells was relatively high (31 %) even af-
ter treatment with a ten times higher OTA concentration
(25 g/mL).
In a subsequent series of experiments we examined
the extent of apoptosis and necrosis, and also the altera-
tions of cell morphology after OTA treatment by haema-
toxylin and eosin or phalloidin-FITC and propidium iodide
staining. Apoptotic cells were also visualized using the
TUNEL assay. Further, the LDH release into the culture
medium, as an indicator of necrotic and/or late apoptotic
processes, was determined. In MDCK, LLC-PK1 and RK
13 cells treated with 2.5 g OTA/mL for 24 hours, 12 %,
11 % and 8.2 % apoptotic cells were observed, respec-
tively (Figures 1b, 2 and 3). The number of apoptotic
cells showed a concentration dependency with the highest
number of apoptotic cells detected after incubation with
5 g OTA/mL for MDCK and LLC-PK1 cells or with
15 g OTA/mL for RK 13 cells. Higher OTA concentra-
tions provoked predominantly necrotic cell death. This was
confirmed by increased LDH release into the culture me-
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Figure 2. OTA induces apoptosis in MDCK and RK 13 cells. MDCK (a, b) and RK 13 (c, d) cells were treated with 2.5, 5, 15 and 25 g
OTA/mL for 24 hours. Cells were stained with haematoxylin and eosin. Representative photomicrographs for untreated control cells (a, c)
and cells treated with 2.5 g OTA/mL (b) or 15 g OTA/mL (d) are shown (magnification 630 x). Apoptotic cells and bodies are more in-
tensively stained (arrows).
(a)
(c)
(b)
(d)
dium. The release of LDH after treatment with OTA was
more abundant in MDCK and LLC-PK1 cells than in
RK 13 cells, indicating a more intensive necrotic process
(Figure 1c). Haematoxylin and eosin staining confirmed a
severe loss of MDCK cells treated with 2.5 g OTA/mL,
while RK 13 cells treated with a six times higher OTA
concentration still showed a large number of adherent cells
and greater resistance to OTA-induced cytotoxicity (Fig-
ure 2). Our results suggest that the effects of OTA are not
exclusively concentration dependent but cell type-speci-
fic as well.
Gekle and colleagues investigated the effects of OTA
in two clones of MDCK kidney cells, with MDCK-C7
cells resembling the principal cells and MDCK-C11 cells
resembling the intercalated cells.36 Apoptosis (measured
by caspase-3 activity and DNA fragmentation), but not
necrosis (measured by LDH leakage), was observed in
MDCK-C7 cells treated with 100 nmol/L OTA. The au-
thors suggested that the c-Jun N-terminal kinase (JNK)
signalling pathway might play a role in OTA-induced
MDCK-C7 cell apoptosis. In contrast, OTA provoked
primarily necrosis in MDCK-C11 cells, which confirms
once again the different susceptibility of cells to OTA.
It has been reported that OTA increased the rate of
both CV-1 cell apoptosis and necrosis within a quite nar-
row concentration range (1–10 µmol/L), which under-
lines that OTAmediated cell death cannot be ascribed ex-
clusively to the induction of apoptosis.31 A research on
cell death induced by ischemic and toxic injuries in renal
tissue also suggests that tubular epithelial cells may die
by either necrosis or apoptosis, depending upon the se-
verity of the injury to which the cells are exposed.41
In our study, OTA induced significant changes of the
cytoskeleton structure, especially in LLC-PK1 cells (Fig-
ure 4). These changes could be caused by a decrease in
intracellular ATP levels,43 activation of caspases44 and/or
activation of calpain.45 Cytoskeletal and cell-membrane
proteins that anchor cytoskeletal elements to the plasma
membrane are excellent substrates for calpain, a Ca2+-
dependent cytosolic cysteine protease. Calpain cleaves
actin-binding proteins ankyrin and spectrin along the ba-
solateral side of the proximal tubule epithelial cells, lead-
ing to membrane damage and internalization of Na+/K+-
ATPase, and consequently to decreased reabsorption of
Na+ and to loss of cell polarity.44 The loss of cell-cell or
cell-matrix connections as well as shrinkage of cells and
apoptosis could also be observed.46 Dopp et al. showed
that the OTA-induced intracellular Ca2+ increase is caus-
ed by Ca2+-release from intracellular stores, as well as
by Ca2+ influx from the extracellular space. It has been
suggested that the disruption of actin filaments after OTA
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Figure 3. OTA induces apoptosis in LLC-PK1 cells. LLC-PK1 cells
were treated with 2.5, 5, 15 and 25 g OTA/mL for 24 hours.
Cells were stained with FITC-dUTP using the TUNEL technique.
Representative photomicrographs for untreated control cells (a)
and cells treated with 2.5 g OTA/mL (b) are shown (magnifica-
tion 500 x). The TUNEL positive nuclei indicating apoptotic cells
are stained yellow-green (arrow).
Figure 4. OTA induces structural changes of actin cytoskeleton.
LLC-PK1 cells were treated with 2.5, 5, 15 and 25 g OTA/mL for
24 hours. Cells were stained simultaneously with phalloidin-FITC
and propidium iodide. Representative photomicrographs for un-
treated control cells (a) and cells treated with 2.5 g OTA/mL (b) are
shown (magnification 400 x). Phalloidin-FITC-labeled actin cyto-
skeleton is changed in OTA-treated cells.
(a)
(b)
treatment does not correlate with the increased intracel-
lular Ca2+. The authors have concluded that OTA disrupts
actin filaments by direct irreversible binding to actin.47
In general, OTA-provoked cytotoxicity can occur with
different scenarios, mostly depending on OTA concentra-
tion: low concentrations induce reversible changes with
preserved homeostasis, then activation of the apoptotic
process occurs, and stimulation of both apoptosis and ne-
crosis, and finally, at higher OTA concentrations the pro-
cesses end in induction of necrotic cell death. Our results
show that 2.5 to 25 g OTA/mL concentrations provok-
ed primarily necrosis, but apoptosis also occurred. The
highest relative ratio of apoptotic to adherent cells was
detected after incubation with 5 g OTA/mL for MDCK
and LLC-PK1 cells or with 15 g OTA/mL for RK 13
cells. Our results suggest that apoptosis and necrosis oc-
cur in a cell type dependent manner.
CONCLUSIONS
OTA induced apoptotic and necrotic processes in MDCK,
LLC-PK1 and RK 13 kidney cells. 2.5 and 5 g/mL OTA
significantly stimulated apoptosis in both LLC-PK1 and
MDCK (morphologically related to proximal and distal
tubule epithelial cells, respectively), and to a lesser ex-
tent in RK 13 cells. Due to the observed anti-mitotic ef-
fect of OTA, the apoptotic process was accelerated and
could play an important role in the development of chro-
nic tubular-interstitial kidney damages. In our study, ne-
crosis occurred primarily when higher OTA concentrations
were applied, with the necrotic process being more in-
tensive in MDCK and LLC-PK1 cells. The results sug-
gest that MDCK and LLC-PK1 cell lines are more sensi-
tive to OTA than the RK 13 cell line and represent a bet-
ter in vitro model for studying the mechanisms of OTA
nephrotoxicity.
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Okratoksin A inducira apoptoti~ko i nekroti~ko umiranje bubre`nih stanica
József Petrik, Ana Mali}, Karmela Bari{i}, Lada Rumora, Tamás Kõszegi, Stjepan Pepeljnjak,
Tihana @ani}-Grubi{i} i Ivana ^epelak
MDCK, LLC-PK1 i RK 13 bubre`ne stanice tretirane su razli~itim koncentracijama OTA (od 2,5 do 25 g
OTA/mL medija) tijekom 24 sata. Koncentracije toksina od 2,5 g/mL uzrokuju zna~ajno smanjenje broja `ivih
stanica u odnosu na netretirane kontrolne uzorke: kod RK 13 stanica broj je smanjen na 69,4 %, kod LLC-PK1
na 34,5 %, a kod MDCK na 27,5 %. Ispitan je u~inak OTA na morfologiju stanica koje su bojane hematoksili-
nom/eozinom odnosno faloidin-FITC/propidijevim jodidom. Kod MDCK, LLC-PK1 i RK 13 stanica tretiranih
s 2,5 g OTA/mL opa`eno je 12 %, 11 % odnosno 8,2 % stanica u apoptozi. OTA je uzrokovao zna~ajne pro-
mjene u strukturi aktinskoga citoskeleta u tretiranim stanicama. OTA je potaknuo istjecanje LDH iz stanica u
okolni medij, {to je osobito izra`eno u MDCK i LLC-PK1 stanicama. Mo`emo zaklju~iti da na~in umiranja
stanica (apoptoza ili nekroza) ovisi o vrsti samih stanica i o primijenjenoj koncentraciji toksina. Na{i rezultati
ukazuju da su MDCK i LLC-PK1 stanice osjetljivije na djelovanje OTA od RK 13 stanica.
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